DiaMedica Therapeutics Inc.
DMAC Nasdaq
SEC CIK 1401040
Follow DiaMedica Therapeutics
Weekly email: filings, results
Net income
−$11.3M
−31.2% vs same quarter last year
EPS, diluted
−$0.21
−23.5% vs same quarter last year
Operating cash flow
−$8.8M
−34.8% vs same quarter last year
Operating income
−$11.6M
−28.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$32.8M |
| FY24 | −$24.4M |
| FY23 | −$19.4M |
| FY22 | −$13.7M |
| FY21 | −$13.6M |
| FY20 | −$12.3M |
| FY19 | −$10.6M |
| FY18 | −$5.7M |
| FY17 | −$4.3M |
| FY16 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$29.1M |
| FY24 | −$22.1M |
| FY23 | −$18.8M |
| FY22 | −$11.6M |
| FY21 | −$12.3M |
| FY20 | −$9.2M |
| FY19 | −$9.1M |
| FY18 | −$5.7M |
| FY17 | −$3.9M |
| FY16 | - |